November 28, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
Company
News Sectors
Automotive
Communications
Consumers
CSR
Electronics
Energy
Environment
Financial
Health & Med
Industrial
IT & Internet
Materials
Real Estate
Science & Research
Telecoms
Trade
Transportation
Departments
Annual Reports
Companies
News Alerts
News Search
Photo Gallery
Client Login
Japan Corporate News Network
About JCN
Privacy Policy
RSS  
Terms of Use
 
 
 

 Headline News

Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Sysmex Corporation and Toppan Printing Co., Ltd. are to cooperate for the advancement in the genetic analysis testing industry, and to invest in RIKEN GENESIS Co., Ltd., a Toppan Printing subsidiary. more info >>
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Takara Bio Inc. has submitted an Investigational New Drug (IND) application to the Food and Drug Administration (FDA) dated April 30, 2014 in order to conduct a phase II clinical trial in the United States of the oncolytic virus HF10 in patients with unresected or metastatic malignant melanoma. more info >>
ACN Newswire
 Press Release News

Eisai Opens New Packaging Facility at Hatfield Production Plant in U.K. (Nov 28, 2014)
Eisai Co., Ltd. announced today that construction of a new packaging facility has been completed at its Hatfield, Hertfordshire production plant in the United Kingdom ahead of plans to launch multiple new Eisai products. more info >>
Eisai Launches Anticancer Agent Halaven as Company's First Product in Brazil (Nov 26, 2014)
Eisai Co., Ltd. announced today that its Brazil subsidiary Eisai Laboratorios Ltda. has launched the anticancer agent Halaven (eribulin mesylate) in the country. more info >>
Eisai Launches Antiepileptic Drug Fycompa in Hong Kong (Nov 21, 2014)
Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the AMPA receptor antagonist Fycompa (perampanel), a first-in-class antiepileptic drug (AED) discovered and developed in-house, in the region as an adjunctive treatment for partial-onset seizures with or without secondary generalized seizures in patients with epilepsy aged 12 years and older. more info >>
JCI Pharmaceutical Co., Ltd. Receives Approval from US FDA for Colloidal Iodine Formulation (Nov 20, 2014)
JCI Pharmaceutical Co., Ltd. has announced approval by the US FDA for its MN colloid iodine (C.I.M.N), a formulation utilizing a world-first technology for converting iodine into a colloidal state to make it absorbable into the body at a large doses. more info >>
Eisai's Ranking Significantly Increases in the Access to Medicine Index 2014 (Nov 17, 2014)
Eisai Co., Ltd. announced today that Eisai has been ranked 11th among the world's leading pharmaceutical companies in the Access to Medicine Index (ATM Index) 2014, representing a significant increase of four places from its previous ranking in 2012. more info >>
 Global Press Release

Eisai Opens New Packaging Facility at Hatfield Production Plant in U.K. (Nov 28, 2014)

Eisai Launches Anticancer Agent Halaven as Company's First Product in Brazil (Nov 26, 2014)

Eisai Launches Antiepileptic Drug Fycompa in Hong Kong (Nov 21, 2014)

JCI Pharmaceutical Co., Ltd. Receives Approval from US FDA for Colloidal Iodine Formulation (Nov 20, 2014)

Eisai's Ranking Significantly Increases in the Access to Medicine Index 2014 (Nov 17, 2014)

JCN Network - Company Profiles - Company Listing
 
CSR Report Download
Most Popular
About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)